SCHEMBL16571553

SCHEMBL16571553

O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CC(NCc2ccncc2)C1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 19/20 0.71
▸ PARP2 Q9UGN5 2/20 0.71
▸ HSP90AA1 P07900 1/20 0.64
▸ HSP90AB1 P08238 1/20 0.64
▸ TNKS O95271 1/20 0.63
▸ ADORA1 P30542 1/20 0.63
▸ CDK6 Q00534 1/20 0.63
▸ PDE3A Q14432 1/20 0.63
▸ PARP6 Q2NL67 1/20 0.63
▸ PARP15 Q460N3 1/20 0.63
▸ PARP14 Q460N5 1/20 0.63
▸ PARP10 Q53GL7 1/20 0.63
▸ TIPARP Q7Z3E1 1/20 0.63
▸ PARP8 Q8N3A8 1/20 0.63
▸ PARP16 Q8N5Y8 1/20 0.63
▸ PARP12 Q9H0J9 1/20 0.63
▸ TNKS2 Q9H2K2 1/20 0.63
▸ PARP11 Q9NR21 1/20 0.63
▸ PARP4 Q9UKK3 1/20 0.63
▸ PARP3 Q9Y6F1 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437346 1.00 PARP1 (0.71) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL16571505 0.94 PARP1 (0.74) PARP1PARP2TNKSADORA1CDK6
SCHEMBL16571947 0.94 PARP1 (0.67) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL30437099 0.94 PARP1 (0.67) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL16571788 0.94 PARP1 (0.67) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL16571790 0.94 PARP1 (0.67) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL30437599 0.91 PARP1 (0.68) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL16571679 0.91 PARP1 (0.68) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL16571770 0.89 PARP1 (0.70) PARP1PARP2HSP90AA1HSP90AB1TNKS
SCHEMBL30436980 0.89 PARP1 (0.70) PARP1PARP2HSP90AA1HSP90AB1TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030557-B1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF IDIENCE CO LTD (KR) 2023-05-31 — — EP disclosed
US-RE49338-E1 Phthalazinone derivatives and manufacturing process thereof IDIENCE CO., LTD. (KR) 2022-12-20 — — US disclosed
US-9844550-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-12-19 — — US disclosed
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2017-06-29 — — US disclosed
US-9682973-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-06-20 — — US disclosed
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2016-08-04 — — US disclosed
EP-3030557-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF Ildong Pharm Co., Ltd. (KR) 2016-06-15 — — EP disclosed
WO-2015037939-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF ILDONG PHARM CO., LTD. (KR) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, PARP1 PARP1 3/4885PARP2 12/4885HSP90AA1 3304/4885
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, NUDT5 PARP1 4/4885PARP2 12/4885HSP90AA1 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback